Biogen Idec hemophilia B treatment wins FDA marketing approval

Biogen Idec hemophilia B treatment wins FDA marketing approval: Biogen Idec said today the U.S. Food and Drug Administration has accepted the company's biologics license application for marketing approval of a fusion protein therapy designed to treat hemophilia B. The FDA also granted the Weston-based company a ...
See all stories on this topic »

Get latest organ donor and transplant news goto -transplantviews.blogspot.com